Decreased anaphylaxis by probiotic Escherichia coli overexpressing Siglec ligand and peanut allergen

Our findings establish proof of concept for orally delivered antigen-specific immune tolerance using engineered probiotics, providing a scalable, noninvasive alternative to intravenous nanoparticle therapies. This approach could be extended to other allergies or autoimmune conditions.